Non-germline genetically engineered mouse models for translational cancer research - PubMed (original) (raw)

Review

Non-germline genetically engineered mouse models for translational cancer research

Joerg Heyer et al. Nat Rev Cancer. 2010 Jul.

Abstract

Genetically engineered mouse models (GEMMs) of cancer have affected virtually all areas of cancer research. However, the accelerated discovery of new cancer genes emerging from large-scale cancer genomics and new chemical entities pouring from the drug discovery pipeline have strained the capacity of traditional germline mouse models to provide crucial insights. This Review introduces new approaches to modelling cancer, with emphasis on a growing collection of non-germline GEMMs (nGEMMs). These offer flexibility, speed and uniformity at reduced costs, thus paving the way for much needed throughput and practical preclinical therapeutic testing models.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

The authors declare competing financial interests; see Web version for details.

Figures

Figure 1

Figure 1. Conditional genetically engineered mouse models (GEMMs)

a | Activating Cre in a tissue-specific manner, by either viral delivery or Cre-oestrogen response element (ERE)-mediated tamoxifen administration. Examples are shown for lung cancer and ovarian cancer, and melanoma. b | Tetracycline (Tet)-mediated transgene inactivation or activation by doxycycline administration or withdrawal using the Tet-On or Tet-Off systems. Examples are shown for liver cancer and melanoma. fl, flox; lsl, lox-STOP-lox; rtTA, reverse transactivator; tTA, transactivator.

Figure 2

Figure 2. Chimeric model generation

a | Genetically modified embryonic stem cells are transduced ex vivo with conditional oncogenic transgenes, injected into blastocysts and implanted into pseudopregnant mice to generate chimeras. b | By activating the respective transgenes in a tissue-specific manner, multiple tumour types can be induced in these chimeras in the context of normal stromal tissue derived from the wild-type blastocysts. Image is modified, with permission, from Nature Biotechnology REF. © (2010) Macmillan Publishers Ltd. All rights reserved. DKO, double knockout; EGFR, epidermal growth factor receptor; Luc, luciferase; rtTA, reverse transactivator; Tet, tetracycline.

Figure 3

Figure 3. Human in mouse transplantation models

Pluripotent human stem cells are grown ex vivo on feeder cells and transduced with the oncogenic elements of interest. Without long culture times, the cells are injected into orthotopic sites on the mice with or without humanized stromal cells. Here, the tumour types of interest will develop from human cells within the context of the relevant mouse or human normal stroma.

Similar articles

Cited by

References

    1. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature Rev Drug Discov. 2006;5:741–754. - PubMed
    1. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet. 2000;24:57–60. - PubMed
    1. Roberts RB, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA. 2002;99:1521–1526. - PMC - PubMed
    1. Jonkers J, Berns A. Conditional mouse models of sporadic cancer. Nature Rev Cancer. 2002;2:251–265. - PubMed
    1. Chin L, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400:468–472. The first conditional transgenic mouse model to demonstrate solid tumour regression on extinction of the initiating oncogene. - PubMed

Publication types

MeSH terms

LinkOut - more resources